Stem-Cell Transplantation
Busulfan pharmacodynamics in children depend on regimen
Published in Blood Weekly, December 25th, 2003
According to published research from France, "A strong relationship has been demonstrated between high systemic exposure to busulfan and the occurrence of hepatic veno-occlusive disease (HVOD) after a busulfan-cyclophosphamide regimen (BU CY)."
J. Bouligand and colleagues at the Gustave Roussy Institute in Villejuif conducted a study "aimed at exploring the pharmacodynamics of high-dose busulfan combined with either melphalan (BU MEL) or thiotepa (BU TTP) followed by autologous stem-cell transplantation in children and adolescents with a malignant solid tumor."
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2003-12-25)
More Articles from Blood Weekly
- Stem Cell Transplantation
Ig-Therasorb treatment useful for post-SCT prolonged red cell aplasia - Stem-Cell Transplantation
Recombinant TAT-HOXB4 protein provides rapid and robust stem-cell expansion - Leukemia Therapy
High stem-cell dose hastens platelet recovery after auto-SCT - Stem-Cell Transplantation
Platelet microparticles could improve donor cell adhesion in cord blood recipients - Stem-Cell Transplantation
Unrelated donor status has limited impact on post-SCT CMV risk - Acute Pancreatitis
Lower HLA-DR on blood monocytes occurs prior to pancreatic organ failure - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
